Not Just a Pretty Face
This article was originally published in The Rose Sheet
Executive Summary
Book chronicling the Campaign for Safe Cosmetics hits shelves this month. Authored by Stacy Malkan, communications director at Health Care Without Harm and co-founder of the Campaign, Not Just a Pretty Face: The Ugly Side of the Beauty Industry (New Society Publishers) asserts that "the $35 billion cosmetics industry is so powerful they've kept themselves unregulated for decades" and highlights "tough questions" extended by the safe cosmetics coalition to industry leaders, including why "companies [that] market themselves as pink-ribbon leaders in the fight against breast cancer ... use hormone-disrupting and carcinogenic chemicals that may contribute to that very disease" and why "companies put chemicals linked to reproductive harm into products used daily by men and women of childbearing age." Consumer advocate Ralph Nader remarks: "This book should be read by women and men who have trusted for too long the companies whose products get inside their bodies and their minds, to the detriment of their health"...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.